Biosimilar epoetin alfa in the management of chemotherapy-induced aneamia: results from ANEMONE observational study

E. Scelzi(Ospedale Castelfranco Veneto), Giovanni Rosti(Ca' Foncello Hospital), Tommaso Raggi(Sanden (Japan)), R. Maisano(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Giorgio Bonciarelli, Teresa Gamucci, Nello Salesi(Tumori Foundation), Daniela Bernardi(Humanitas University), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Manlio Mencoboni(Villa Torri Hospital), P Tagliaferri

Annals of Oncology

October 1, 2015

10.1093/annonc/mdv346.29

Cited by 1

Related Papers

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

|Journal of Clinical Oncology|2012|368

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

|Annals of Oncology|2012|339

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

|The Lancet Oncology|2020|333

Early nutritional intervention improves treatment tolerance and outcomes in head and neck cancer patients undergoing concurrent chemoradiotherapy

|Supportive Care in Cancer|2009|266

Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy

|Cancer Research|2010|244